Skip to Content
Merck

Circulating Glioma Cells Exhibit Stem Cell-like Properties.

Cancer research (2018-10-17)
Tianrun Liu, Haineng Xu, Menggui Huang, Wenjuan Ma, Deeksha Saxena, Robert A Lustig, Michelle Alonso-Basanta, Zhenfeng Zhang, Donald M O'Rourke, Lin Zhang, Yanqing Gong, Gary D Kao, Jay F Dorsey, Yi Fan
ABSTRACT

: Circulating tumor cells (CTC) are known to be present in the blood of patients with glioblastoma (GBM). Here we report that GBM-derived CTC possess a cancer stem cell (CSC)-like phenotype and contribute to local tumorigenesis and recurrence by the process of self-seeding. Genetic probes showed that mouse GBM-derived CTC exhibited Sox2/ETn transcriptional activation and expressed glioma CSC markers, consistent with robust expression of stemness-associated genes including SOX2, OCT4, and NANOG in human GBM patient-derived samples containing CTC. A transgenic mouse model demonstrated that CTC returned to the primary tumor and generated new tumors with enhanced tumorigenic capacity. These CTCs were resistant to radiotherapy and chemotherapy and to circulation stress-induced cell apoptosis. Single-cell RNA-seq analysis revealed that Wnt activation induced stemness and chemoresistance in CTC. Collectively, these findings identify GBM-derived CTC as CSC-like cells and suggest that targeting Wnt may offer therapeutic opportunities for eliminating these treatment-refractory cells in GBM. SIGNIFICANCE: These findings identify CTCs as an alternative source for in situ tumor invasion and recurrence through local micrometastasis, warranting eradication of systemic "out-of-tumor" CTCs as a promising new therapeutic opportunity for GBM.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-GFP (Green Fluorescent Protein) Antibody, Upstate®, from chicken
Sigma-Aldrich
Anti-Ki-67 Antibody, Chemicon®, from rabbit